Nkarta's NKX019 offers hope for autoimmune treatment. Upcoming trial data and strategic moves could fuel recovery. Read more ...

FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track – – Enrolling approximately one patient per week across the RESET™ clinical development program since ACR ...